MT1 and MT2 melatonin receptors: Ligands, models, oligomers, and therapeutic potential

Journal of Medicinal Chemistry

Volumn 57, Issue 8, 2014, Pages 3161-3185

  Zlotos, Darius P ^a   Jockers, Ralf ^b,c,d   Cecon, Erika ^e   Rivara, Silvia ^f   Witt Enderby, Paula A ^g  

^a German University in Cairo   (Egypt)

^b INSTITUT COCHIN   (France)

^c CNRS   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f UNIVERSITY OF PARMA   (Italy)

^g DUQUESNE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN DERIVATIVE; RAMELTEON; TASIMELTEON; LIGAND;

BINDING AFFINITY; BINDING SITE; CARDIOVASCULAR DISEASE; DEGENERATIVE DISEASE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; LIGAND BINDING; NEOPLASM; NONHUMAN; OBESITY; OLIGOMERIZATION; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DEPRESSION; DRUG EFFECT; INSOMNIA; PHYSIOLOGY; PROTEIN MULTIMERIZATION;

ANIMALS; BINDING SITES; DEPRESSIVE DISORDER; HUMANS; LIGANDS; MELATONIN; MODELS, MOLECULAR; PROTEIN MULTIMERIZATION; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; SLEEP INITIATION AND MAINTENANCE DISORDERS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84899512881     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401343c     Document Type: Review

References (203)

1. McCord, C. P.; Allen, F. P. Evidence associating pineal gland function with alterations in pigmentation. J. Exp. Zool. 1917, 23, 207-224.
2. Lerner, A. B.; Case, J. D.; Takahashi, Y.; Lee, T. H.; Mori, W. Isolation of melatonin, the pineal gland factor that lightens melanocytes. J. Am. Chem. Soc. 1958, 80, 2587.
3. Lerner, A. B.; Case, J. D. Structure of melatonin. J. Am. Chem. Soc. 1959, 81, 6084.
4. Claustrat, B.; Brun, J.; Chazot, G. The basic physiology and pathophysiology of melatonin. Sleep Med. Rev. 2005, 9, 11-24.
5. Pandi-Perumal, S. R; Srinivasan, V.; Maestroni, G. J. M.; Cardinali, D. P.; Poeggeler, B.; Hardeland, R. Melatonin: nature's most versatile biological signal? FEBS J. 2006, 273, 2813-2838.
6. Hirata, F.; Hayaishi, O.; Tokuyama, T.; Seno, S. In vitro and in vivo formation of two new metabolites of melatonin. J. Biol. Chem. 1974, 249, 1311-1313.
7. Tan, D. X.; Manchester, L. C; Reiter, R J.; Plummer, B. F.; Hardies, L. J.; Weintraub, S. T.; Vijayalaxmi; Shepherd, A. M. A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation. Biochem. Biophys. Res. Commun. 1998, 253, 614-620.
8. Reppert, S. M.; Weaver, D. R; Godson, C. Melatonin receptors step into the light: cloning and classification of subtypes. Trends Pharmacol. Sci. 1996, 17, 100-102.
9. Nosjean, O.; Ferro, M.; Coge, F.; Beauverger, P.; Henlin, J. M.; Lefoulon, F.; Fauchere, J. L.; Delagrange, P.; Canet, E.; Boutin, J. A. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J. Biol. Chem. 2000, 275, 31311-31317.
10. Dubocovich, M. L.; Delagrange, P.; Krause, D. N.; Sugden, D.; Cardinali, D. P.; Olcese, J. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol. Rev. 2010, 62, 343-380.
11. Pandi-Perumal, S. R; Trakht, I.; Srinivasan, V.; Spence, D. W.; Maestroni, G J. M.; Zisapel, N.; Cardinali, D. P. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog. Neurobiol. 2008, 85, 335-353.
12. Calvo, J. R; Gonzalez-Yanes, C.; Maldonado, M. D. The role of melatonin in the cells of the innate immunity: a review. J. Pineal Res. 2013, 55, 103-120.
13. Grant, S. G; Melan, M. A.; Latimer, J. J.; Witt-Enderby, P. A. Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives. Expert Rev. Mol. Med. 2009, 11, e5.
14. Witt-Enderby, P. A.; Radio, N. M.; Doctor, J. S; Davis, V. L. Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant Therapy. J. Pineal Res. 2006, 41, 297-305.
15. Davis, V. L.; Dodda, B. R; Witt-Enderby, P. A. The Prevention and Treatment of Breast Cancer Using Melatonin. In Melatonin in the Promotion of Health; 2nd ed.; Watson, R, Ed.; Taylor and Francis Press: Abingdon, Oxon, U.K., 2011; pp 271-286.
16. Karamitri, A.; Renault, N.; Clement, N.; Guillaume, J. L.; Jockers, R Toward the establishment of a link between melatonin and glucose homeostasis: association of melatonin MT2 receptor variants with type 2 diabetes. Mol. Endocrinol. 2013, 27, 1217-1233.
17. Witt-Enderby, P. A.; Clafshenkel, W. P.; Kotlarczyk, M. P.; Sethi, S. Melatonin in Bone Health. In Melatonin in the Promotion of Health, 2nd ed.; Watson, R, Ed.; Taylor and Francis Press: Abingdon, Oxon, U.K., 2011; pp261-270.
18. Cavanaugh, J.; Witt-Enderby, P. A. CNS melatonin receptors and signaling: focus on aging-related diseases and future perspectives. Open Neuroendocrinol. J. 2010, 3, 96-104.
19. Brydon, L.; Roka, F.; Petit, L.; deCoppet, P.; Tissot, M.; Barrett, P.; Morgan, P. J.; Nanoff, C.; Strosberg, A. D.; Jockers, R Dual signaling of human Mel1a melatonin receptors via G(I2), G(I3), and G(Q/11) proteins. Mol. Endocrinol. 1999, 13, 2025-2038.
20. Levoye, A; Dam, J.; Ayoub, M. A.; Guillaume, J. L.; Couturier, C.; Delagrange, P.; Jockers, R The orphan GPR50 receptor specifically inhibits MT(1) melatonin receptor function through heterodimeriza-tion. EMBO J. 2006, 25, 3012-3023.
21. Kamal, M.; Marquez, M.; Vauthier, V.; Leloire, A.; Froguel, P.; Jockers, R; Couturier, C. Improved donor/acceptor BRET couples for monitoring /7-arrestin recruitment to G protein-coupled receptors. Biotechnol. J. 2009, 4, 1337-1344.
22. Sethi, S.; Radio, N. M.; Kotlarczyk, M. P.; Chen, C. T.; Wei, Y. H; Jockers, R; Witt-Enderby, P. A Determination of the minimal melatonin exposure required to induce osteoblast differentiation from human mesenchymal stem cells and these effects on downstream signaling pathways. J. Pineal Res. 2010, 49, 222-238.
23. Maurice, P.; Daulat, A. M.; Turecek, R.; Ivankova-Susankova, K.; Zamponi, F.; Kamal, M.; Clement, N.; Guillaume, J. L.; Bettler, B.; Gales, C.; Delagrange, P.; Jockers, R. Molecular organization and dynamics of the melatonin MT receptor/RGS20/G(i) protein complex reveal asymmetry of receptor dimers for RGS and G(i) coupling. EMBO J. 2010, 29, 3646-3659.
24. Vakkuri, O.; Leppaluoto, J.; Vuolteenaho, O. Development and validation of a melatonin radioimmunoassay using radioiodinated melatonin as a tracer. Acta Endrocrinol. 1984, 106, 152-157.
25. Roka, F.; Brydon, L.; Waldhoer, M.; Strosberg, A. D.; Freissmuth, M.; Jockers, R.; Nanoff, C. Tight association of the human Mel(1a)-melatonin receptor and G(i): precoupling and constitutive activity. Mol. Pharmacol. 1999, 56, 1014-1024.
26. Cardinali, D. P.; Vacas, M. I.; Boyer, E. E. Specific binding of melatonin in bovine brain. Endocrinology 1979, 105, 437-441.
27. Legros, C.; Matthey, U.; Grelak, T.; Pedragona-Moreau, S.; Hassler, W.; Yous, S.; Thomas, E.; Suzenet, F.; Folleas, B.; Lefoulon, F.; Berthelot, P.; Caignard, D. H.; Guillaumet, G.; Delagrange, P.; Brayer, J. L.; Nosjean, O.; Boutin, J. A. New radioligands for describing the molecular pharmacology of MT1 and MT2 melatonin receptors. Int. J. Mol. Sci. 2013, 14, 8948-8962.
28. Jockers, R.; Maurice, P.; Boutin, J. A.; Delagrange, P. Melatonin receptors, heterodimerization, signal transduction and binding sites: What's new? Br. J. Pharmacol. 2008, 154, 1182-1195.
29. Kopin, I. J.; Pare, C. M.; Axelrod, J.; Weissbach, H. The fate of melatonin in animals. J. Biol. Chem. 1961, 236, 3072-3075.
30. Niles, L. P.; Wong, Y. W.; Mishra, R. K.; Brown, G. M. Melatonin receptors in brain. Eur. J. Pharmacol. 1979, 55, 219-220.
31. Browning, C.; Beresford, I.; Fraser, N.; Giles, H. Pharmacological characterization of human recombinant melatonin mt(1) and MT2 receptors. Br. J. Pharmacol. 2000, 129, 877-886.
32. Liu, C.; Weaver, D. R.; Jin, X.; Shearman, L. P.; Pieschl, R. L.; Gribkoff, V. K.; Reppert, S. M. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 1997, 19, 91-102.
33. Lotufo, C. M.; Lopes, C.; Dubocovich, M. L.; Farsky, S. H.; Markus, R. P. Melatonin and N-acetylserotonin inhibit leukocyte rolling and adhesion to rat microcirculation. Eur. J. Pharmacol. 2001, 430, 351-357.
34. Bahr, I.; Muhlbauer, E.; Albrecht, E.; Peschke, E. Evidence of the receptor-mediated influence of melatonin on pancreatic glucagon secretion via the Galphaq protein-coupled and PI3K signaling pathways. J. Pineal Res. 2012, 53, 390-398.
35. Imbesi, M.; Uz, T.; Dzitoyeva, S.; Giusti, P.; Manev, H. Melatonin signaling in mouse cerebellar granule cells with variable native MT1 and MT2 melatonin receptors. Brain Res. 2008, 1227, 19-25.
36. Thomas, L.; Purvis, C. C.; Drew, J. E.; Abramovich, D. R.; Williams, L. M. Melatonin receptors in human fetal brain: 2-[I-125] iodomelatonin binding and MT1 gene expression. J. Pineal Res. 2002, 33, 218-224.
37. Hill, S. M.; Cheng, C.; Yuan, L.; Mao, L.; Jockers, R.; Dauchy, B.; Frasch, T.; Blask, D. E. Declining melatonin levels and MT1 receptor expression in aging rats is associated with enhanced mammary tumor growth and decreased sensitivity to melatonin. Breast Cancer Res. Treat. 2011, 127, 91-98.
38. (a) Savaskan, E.; Jockers, R.; Ayoub, M.; Angeloni, D.; Fraschini, F.; Flammer, J.; Eckert, A.; Muller-Spahn, F.; Meyer, P. The MT2 melatonin receptor subtype is present in human retina and decreases in Alzheimer's disease. Curr. Alzheimer Res. 2007, 4, 47-51.
39. (b) Savaskan, E.; Ayoub, M. A.; Ravid, R.; Angeloni, D.; Fraschini, F.; Meier, F.; Eckert, A.; Muller-Spahn, F.; Jockers, R. Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease. J. Pineal Res. 2005, 38, 10-16.
40. Wang, X.; Sirianni, A.; Pei, Z.; Cormier, K.; Smith, K.; Jiang, J.; Zhou, S.; Wang, H.; Zhao, R.; Yano, H.; Kim, J. E.; Li, W.; Kristal, B. S.; Ferrante, R. J.; Friedlander, R. M. The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity. J. Neurosci. 2011, 31, 14496-14507.
41. Adi, N.; Mash, D. C.; Ali, Y.; Singer, C.; Shehadeh, L.; Papapetropoulos, S. Melatonin MT1 and MT2 receptor expression in Parkinson's disease. Med. Sci. Monit. 2010, 16, BR61-BR67.
42. Wu, Y. H.; Ursinus, J.; Zhou, J. N.; Scheer, F. A.; Ai-Min, B.; Jockers, R.; van Heerikhuize, J.; Swaab, D. F. Alterations of melatonin receptors MT1 and MT2 in the hypothalamic suprachiasmatic nucleus during depression. J. Affective Disord. 2013, 148, 357-367.
43. Lanoix, D.; Guerin, P.; Vaillancourt, C. Placental melatonin production and melatonin receptor expression are altered in preeclampsia: new insights into the role of this hormone in pregnancy. J. Pineal Res. 2012, 53, 417-425.
44. Dillon, D. C.; Easley, S. E.; Asch, B. B.; Cheney, R. T.; Brydon, L.; Jockers, R.; Winston, J. S.; Brooks, J. S.; Hurd, T.; Asch, H. L. Differential expression of high-affinity melatonin receptors (MT1) in normal and malignant human breast tissue. Am. J. Clin. Pathol. 2002, 118, 451-458.
45. Schuster, C.; Gauer, F.; Guerrero, H.; LakhdarGhazal, N.; Pevet, P.; MassonPevet, M. Photic regulation of mt(1) melatonin receptors in the Siberian hamster pars tuberalis and suprachiasmatic nuclei: involvement of the circadian clock and intergeniculate leaflet. J. Neuroendocrinol. 2000, 12, 207-216.
46. Rasmussen, S. G.; DeVree, B. T.; Zou, Y.; Kruse, A. C.; Chung, K. Y.; Kobilka, T. S.; Thian, F. S.; Chae, P. S.; Pardon, E.; Calinski, D.; Mathiesen, J. M.; Shah, S. T.; Lyons, J. A.; Caffrey, M.; Gellman, S. H.; Steyaert, J.; Skiniotis, G.; Weis, W. I.; Sunahara, R. K.; Kobilka, B. K. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 2011, 477, 549-555.
47. Whorton, M. R.; Bokoch, M. P.; Rasmussen, S. G.; Huang, B.; Zare, R. N.; Kobilka, B.; Sunahara, R. K. A monomeric G proteincoupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 7682-7687.
48. Bayburt, T. H.; Leitz, A. J.; Xie, G.; Oprian, D. D.; Sligar, S. G. Transducin activation by nanoscale lipid bilayers containing one and two rhodopsins. J. Biol. Chem. 2007, 282, 14875-14881.
49. Bayburt, T. H.; Vishnivetskiy, S. A.; McLean, M. A.; Morizumi, T.; Huang, C. C.; Tesmer, J. J.; Ernst, O. P.; Sligar, S. G.; Gurevich, V. V. Monomeric rhodopsin is sufficient for normal rhodopsin kinase (GRK1) phosphorylation and arrestin-1 binding. J. Biol. Chem. 2011, 286, 1420-1428.
50. Kamal, M.; Jockers, R. Biological significance of GPCR heteromerization in the neuro-endocrine system. Front. Endocrinol. 2011, 2, 2.
51. Ayoub, M. A.; Couturier, C.; Lucas-Meunier, E.; Angers, S.; Fossier, P.; Bouvier, M.; Jockers, R. Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. J. Biol. Chem. 2002, 277, 21522-21528.
52. Ayoub, M. A.; Levoye, A.; Delagrange, P.; Jockers, R. Preferential formation of MT1/MT2 melatonin receptor heterodimers with distinct ligand interaction properties compared with MT2 homodimers. Mol. Pharmacol. 2004, 66, 312-321.
53. Milligan, G. The prevalence, maintenance and relevance of GPCR oligomerization. Mol. Pharmacol. 2013, 84, 158-169.
54. Bulenger, S.; Marullo, S.; Bouvier, M. Emerging role of homoand heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol. Sci. 2005, 26, 131-137.
55. Maurice, P.; Kamal, M.; Jockers, R. Asymmetry of GPCR oligomers supports their functional relevance. Trends Pharmacol. Sci. 2011, 32, 514-520.
56. Baba, K.; Benleulmi-Chaachoua; Journe, A. S.; Kamal, M.; Guillaume, J. L.; Dussaud, S.; Gbahou, F.; Yettou, K.; Liu, C.; Contreras-Alcantara, S.; Jockers, R.; Tosini, G. Heteromeric MT1/ MT2 melatonin receptors modulate photoreceptor function. Sci. Signaling 2013, 6 (296), ra89.
57. Levoye, A.; Jockers, R.; Ayoub, M. A.; Delagrange, P.; Savaskan, E.; Guillaume, J. L. Are G protein-coupled receptor heterodimers of physiological relevance? Focus on melatonin receptors. Chronobiol. Int. 2006, 23, 419-426.
58. Reppert, S. M.; Weaver, D. R; Rivkees, S. A.; Stopa, E. G. Putative melatonin receptors in a human biological clock. Science 1988, 242, 78-81.
59. Musshoff, U.; Riewenherm, D.; Berger, E.; Fauteck, J. D.; Speckmann, E. J. Melatonin receptors in rat hippocampus: molecular and functional investigations. Hippocampus 2002, 12, 165-173.
60. Dubocovich, M. L. Melatonin is a potent modulator of dopamine release in the retina. Nature 1983, 306, 782-784.
61. Brydon, L.; Petit, L.; Delagrange, P.; Strosberg, A D.; Jockers, R Functional expression of mt2 (mel1b) melatonin receptors in human paz6 adipocytes. Endocrinology 2001, 142, 4264-4271.
62. Adachi, A; Natesan, A. K.; Whitfield-Rucker, M. G.; Weigum, S. E.; Cassone, V. M. Functional melatonin receptors and metabolic coupling in cultured chick astrocytes. Glia 2002, 39, 268-278.
63. Katritch, V.; Cherezov, V.; Stevens, R C. Structure-function of the G protein-coupled receptor superfamily. Annu. Rev. Pharmacol. Toxicol. 2013, 53, 531-556.
64. Maeda, S.; Schertler, G F. Production of GPCR and GPCR complexes for structure determination. Curr. Opin. Struct. Biol. 2013, 23, 381-392.
65. (a) Kufareva, I.; Rueda, M.; Katritch, V.; Stevens, R C.; Abagyan, R Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assessment. Structure 2011, 19, 1108-1126.
66. (b) Beuming, T.; Sherman, W. Current assessment of docking into GPCR crystal structures and homology models: successes, challenges, and guidelines. J. Chem. Inf. Model. 2012, 52, 3263-3277.
67. Ballesteros, J. A.; Weinstein, H. Integrated Methods for the Construction of Three-Dimensional Models and Computational Probing of Structure-Function Relations in G Protein-Coupled Receptors. In Methods in Neurosciences; Sealfon, S. C., Conn, P. M., Eds.; Academic Press: San Diego, CA, 1995; Vol. 25, pp 366-428.
68. 1a melatonin receptor. Biochem. Biophys. Res. Commun. 1997, 239, 418-423.
69. Kokkola, T.; Foord, S. M.; Watson, M.-A.; Vakkuri, O.; Laitinen, J. T. Important amino acids for the function of the human MT1 melatonin receptor. Biochem. Pharmacol. 2003, 65, 1463-1471.
70. 1 receptor. Biochem. Biophys. Res. Commun. 2001, 282, 1229-1236.
71. 2 melatonin receptor. Biochem. Pharmacol. 2003, 66, 315-320.
72. Mazna, P.; Obsilova, V.; Jelinkova, I.; Balik, A.; Berka, K.; Sovova, Z.; Ettrich, R; Svoboda, P.; Obsil, T.; Teisinger, J. Molecular modeling of human MT2 melatonin receptor: the role of Val204, Leu272 and Tyr298 in ligand binding. J. Neurochem. 2004, 91, 836-842.
73. Mazna, P.; Berka, K.; Jelinkova, I.; Balik, A; Svoboda, P.; Obsilova, V.; Obsil, T.; Teisinger, J. Ligand binding to the human MT2 melatonin receptor: the role of residues in transmembrane domains 3, 6, and 7. Biochem. Biophys. Res. Commun. 2005, 332, 726-734.
74. Grol, C. J.; Jansen, J. M. The high affinity melatonin binding site probed with conformationally restricted ligands-II. Homology modeling of the receptor. Bioorg. Med. Chem. 1996, 4, 1333-1339.
75. Sugden, D.; Chong, N. W. S.; Lewis, D. F. V. Structural requirements at the melatonin receptor. Br. J. Pharmacol. 1995, 114, 618-623.
76. Navajas, C.; Kokkola, T.; Poso, A; Honka, N.; Gynther, J.; Laitinen, J. T. A rhodopsin-based model for melatonin recognition at its G protein-coupled receptor. Eur. J. Pharmacol. 1996, 304, 173-183.
77. Pala, D.; Lodola, A.; Bedini, A.; Spadoni, G; Rvara, S. Homology models of melatonin receptors: challenges and recent advances. Int. J. Mol. Sci. 2013, 14, 8093-8121.
78. Uchikawa, O.; Fukatsu, K.; Tokunoh, R.; Kawada, M.; Matsumoto, K.; Imai, Y.; Hinuma, S.; Kato, K.; Nishikawa, H.; Hirai, K.; Miyamoto, M.; Ohkawa, S. Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists. J. Med. Chem. 2002, 45, 4222-4239.
79. Ivanov, A. A.; Voronkov, A. E.; Baskin, I. I.; Palyulin, V. A.; Zefirov, N. S. The study of the mechanism of binding of human ML1A melatonin receptor ligands using molecular modeling. Dokl. Biochem. Biophys. 2004, 394, 49-52.
80. Voronkov, A. E.; Ivanov, A. A.; Baskin, I. I.; Palyulin, V. A.; Zefirov, N. S. Molecular modeling study of the mechanism of ligand binding to human melatonin receptors. Dokl. Biochem. Biophys. 2005, 403, 284-288.
81. Chugunov, A. O.; Farce, A.; Chavatte, P.; Efremov, R. G. Differences in binding sites of two melatonin receptors help to explain their selectivity to some melatonin analogs: a molecular modeling study. J. Biomol. Struct. Dyn. 2006, 24, 91-107.
82. 2 receptors. Eur. J. Med. Chem. 2008, 43, 1926-1944.
83. 1-selective melatonin receptor ligands: synthesis, pharmacological evaluation, and molecular dynamics investigation of N-{[(3-O-substituted) anilino]alkyl}amides. ChemMedChem 2012, 7, 1954-1964.
84. Zefirova, O. N.; Baranova, T. Y.; Ivanova, A. A.; Ivanov, A. A.; Zefirov, N. S. Application of the bridgehead fragments for the design of conformationally restricted melatonin analogues. Bioorg. Chem. 2011, 39, 67-72.
85. 2 receptor models. J. Med. Chem. 2005, 48, 4049-4060.
86. Rivara, S.; Mor, M.; Silva, C.; Zuliani, V.; Vacondio, F.; Spadoni, G.; Bedini, A.; Tarzia, G.; Lucini, V.; Pannacci, M.; Fraschini, F.; Plazzi, P. V. Three-dimensional quantitative structure-activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: requirements for subtype selectivity and Intrinsic activity modulation. J. Med. Chem. 2003, 46, 1429-1439.
87. Katritch, V.; Rueda, M.; Lam, P. C.-H.; Yeager, M.; Abagyan, R. GPCR 3D homology models for ligand screening: lessons learned from blind predictions of adenosine A2a receptor complex. Proteins 2010, 78, 197-211.
88. Jansen, J. M.; Copinga, S.; Gruppen, G.; Molinari, E. J.; Dubocovich, M. L.; Grol, C. J. The high affinity melationin binding site probed with conformationally restricted ligand-I. Pharmacophore and minireceptor models. Bioorg. Med. Chem. 1996, 4, 1321-1332.
89. Spadoni, G.; Balsamini, C.; Diamantini, G.; Di Giacomo, B.; Tarzia, G.; Mor, M.; Plazzi, P. V.; Rivara, S.; Lucini, V.; Nonno, R.; Pannacci, M.; Fraschini, F.; Stankov, B. M. Conformationally restrained melatonin analogs: synthesis, binding affinity for the melatonin receptor, evaluation of the biological activity, and molecular modeling study. J. Med. Chem. 1997, 40, 1990-2002.
90. Rivara, S.; Diamantini, G.; Di Giacomo, B.; Lamba, D.; Gatti, G.; Lucini, V.; Pannacci, M.; Mor, M.; Spadoni, G.; Tarzia, G. Reassessing the melatonin pharmacophore-enantiomeric resolution, pharmacolog ical activity, structure analysis, and molecular modeling of a constrained chiral melatonin analogue. Bioorg. Med. Chem. 2006, 14, 3383-3391.
91. Bedini, A.; Lucarini, S.; Spadoni, G.; Tarzia, G.; Scaglione, F.; Dugnani, S.; Pannacci, M.; Lucini, V.; Carmi, C.; Pala, D.; Rivara, S.; Mor, M. Toward the definition of stereochemical requirements for MT2-selective antagonists and partial agonists by studying 4-phenyl-2-propionamidotetralin (4-P-PDOT) derivatives. J. Med. Chem. 2011, 54, 8362-8372.
92. Pala, D.; Beuming, T.; Sherman, W.; Lodola, A.; Rivara, S.; Mor, M. Structure-based virtual screening of MT2 melatonin receptor: influence of template choice and structural refinement. J. Chem. Inf. Model. 2013, 53, 821-835.
93. Naylor, S.; Gleich, G. J. Over-the-counter melatonin products and contamination. Am. Fam. Physician 1999, 59, 287-288.
94. Williamson, B. L.; Tomlinson, A. J.; Mishra, P K.; Gleich, G J.; Naylor, S. Structural characterization of contaminants found in commercial preparations of melatonin: similarities to case-related compounds from L-tryptophan associated with eosinophilia-myalgia syndrome. Chem. Res. Toxicol. 1998, 11, 234-240.
95. Hardeland, R. New approaches in the management of insomnia: weighing the advantages of prolonged release melatonin and synthetic melatoninergic agonists. Neuropsychiatr. Dis. Treat. 2009, 5, 341-354.
96. Rivara, S.; Mor, M.; Bedini, A.; Spadoni, G.; Tarzia, G. Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. Curr. Top. Med. Chem. 2008, 8, 954-968.
97. 2receptor agonists. Expert Opin. Ther. Pat. 2010, 20, 1059-1077.
98. Hardeland, R. Investigational melatonin receptor agonists. Expert Opin. Invest. Drugs 2010, 19, 747-764.
99. 2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci. Ther. 2009, 15, 32-51.
100. Karim, A.; Tolbert, D.; Cao, C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J. Clin. Pharmacol 2006, 46, 140-148.
101. Cardinali, D. P.; Srinivasan, V.; Brzezinski, A.; Brown, G. M. Melatonin and its analogs in insomnia and depression. J. Pineal Res. 2012, 52, 365-375.
102. de Bodinat, C.; Guardiola-Lemaitre, B.; Mocaer, E.; Renard, P.; Munoz, C.; Millan, M. J. Agomelatine, the first melatonergic antidepressant: discovery characterization and development. Nat. Rev. Drug Discovery 2010, 9, 628-642.
103. Lankford, D. A. Tasimelteon for insomnia. Expert Opin. Invest. Drugs 2011, 20, 987-993.
104. Zemlan, F. P.; Mulchahey, J. J.; Scharf, M. B.; Mayleben, D. W.; Rosenberg, R.; Lankford, A. The efficacy and safety of the melatonin agonist β-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. J. Clin. Psychiatry 2005, 66, 384-390.
105. Rajaratnam, S. M. W.; Polymeropoulos, M. H.; Fisher, D. M.; Roth, T.; Scott, C.; Birznieks, G.; Klerman, E. B. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet 2009, 373, 482-491.
106. NASDAQ News & Commentary. http://www.nasdaq.com/ article/vanda- pharma-submits-nda-for-circadian-regulator-tasimelteon-in-totally-blind- 20130531-00146.
107. Landolt, H. P.; Wehrle, R. Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood? Eur. J. Neurosci. 2009, 29, 1795-1809.
108. Zlotos, D. P. Recent advances in melatonin receptor ligands. Arch. Pharm. Chem. Life Sci. 2005, 338, 229-247.
109. Garrat, P. J.; Tsotinis, A. Synthesis of compounds as melatonin agonists and antagonists. Mini-Rev. Med. Chem. 2007, 7, 1075-1088.
110. Mor, M.; Rivara, S.; Silva, C.; Bordi, F.; Plazzi, P. V.; Spadoni, G.; Diamantini, G.; Balsamini, C.; Tarzia, G.; Fraschini, F.; Lucini, V.; Nonno, R.; Stankov, B. M. Melatonin receptor ligands: synthesis of new melatonin derivatives and comprehensive comparative molecular field analysis (CoMFA) study. J. Med. Chem. 1998, 41, 3831-3844.
111. Zlotos, D. P. Recent progress in the development of agonists and antagonists for melatonin receptors. Curr. Med. Chem. 2012, 19, 3532-3549.
112. Dubocovich, M. L.; Masana, M. I.; Iacob, S.; Sauri, D. M. Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profileof the rabbit retina ML1 presynaptic heteroreceptor. Naunyn-Schmiedeberg's Arch. Pharmacol. 1997, 355, 365-375.
113. Tsotinis, A.; Vlachou, M.; Papahatjis, D. P.; Calogeropoulou, T.; Nikas, S. P.; Garratt, P. J.; Piccio, V.; Vonhoff, S.; Davidson, K.; Teh, M. T.; Sugden, D. Mapping the melatonin receptor. 7. Subtype selective ligands based on β-substituted N-acyl-5-methoxytryptamines and N-acyl-5-methoxy-1-methyl- tryptamines. J. Med. Chem. 2006, 49, 3509-3519.
114. Depreux, P.; Lesieur, D.; Mansour, H. A.; Morgan, P.; Howell, H. E.; Renard, P.; Caignard, D.-H.; Pfeiffer, B.; Delagrange, P.; Guardiola, B.; Yous, S.; Demarque, A.; Adam, G.; Andrieux, J. Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands. J. Med. Chem. 1994, 37, 3231-3239.
115. 2 melatonin receptor selective ligands. J. Med. Chem. 2002, 45, 2788-2800.
116. Fourmaintraux, E.; Depreux, P.; Lesieur, D.; Guardiola-Lemaître, B.; Bennejean, C.; Delagrange, P.; Howell, H. Tetrahy-dronaphthalenic derivatives as new agonist and antagonist ligands for melatonin receptors. Bioorg. Med. Chem. 1998, 6, 9-13.
117. Li, P.-K.; Chu, G.-H.; Gillen, M. L.; Witt-Enderby, P. A. Synthesis and receptor binding studies of quinolinic derivatives as melatonin receptor ligands. Bioorg. Med. Chem. Lett. 1997, 7, 2177-2180.
118. El Kazzouli, S.; du Bellay, A. G.; Berteina-Raboin, S.; Delagrange, P.; Caignard, D. H.; Guillaumet, G. Design and synthesis of 2-phenylimidazo[1, 2-a]pyridines as a novel class of melatonin receptor ligands. Eur. J. Med. Chem. 2011, 46, 4252-4257.
119. Elsner, J.; Boeckler, F.; Davidson, K.; Sugden, D.; Gmeiner, P. Bicyclic melatonin receptor agonists containing a ring-junction nitrogen: synthesis, biological evaluation, and molecular modelling of the putative bioactive conformation. Bioorg. Med. Chem. 2006, 14, 1949-1958.
120. 2-selective agonists. J. Med. Chem. 2011, 54, 3436-3444.
121. Koike, T.; Takai, T.; Hoashi, Y.; Nakayama, M.; Kosugi, Y.; Nakashima, M.; Yoshikubo, S.; Hirai, K.; Uchikawa, O. Synthesis of a novel series of tricyclic dihydrofuran derivatives: discovery of 8, 9-dihydrofuro[3, 2-c]pyrazolo[1, 5-a]pyridines as melatonin receptor (MT1/MT2) Ligands. J. Med. Chem. 2011, 54, 4207-4218.
122. Tarzia, G.; Diamantini, G.; Di Giacomo, B.; Spadoni, G.; Esposti, D.; Nonno, R.; Lucini, V.; Pannacci, M.; Fraschini, F.; Stankov, B. M. 1-(2-Alkanamidoethyl)-6-methoxyindole derivatives: a new class of potent indole melatonin analogues. J. Med. Chem. 1997, 40, 2003-2010.
123. Jeanty, M.; Suzenet, F.; Delagrange, F.; Nosjean, O.; Boutin, J. A.; Caignard, D. H.; Guillaumet, G. Design and synthesis of 1-(2-alkanamidoethyl)-6- methoxy-7-azaindolederivatives as potent melato-nin agonists. Bioorg. Med. Chem. Lett. 2011, 21, 2316-2319.
124. Garratt, P. J.; Travard, S.; Vonhoff, S.; Tsotinis, A.; Sugden, D. Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides. J. Med. Chem. 1996, 39, 1797-1805.
125. Charton, I.; Mamai, A.; Bennejean, C.; Renard, P.; Howell, E. H.; Guardiola-Lemaitre, B.; Delagrange, P.; Morgan, P. J.; Viaud, M.C.; Guillaumet, G. Substituted oxygenated heterocycles and thio-analogues: synthesis and biological evaluation as melatonin ligands. Bioorg. Med. Chem. 2000, 8, 105-114.
126. Charton, I.; Suzenet, F.; Boutin, J.; Audinot, V.; Delagrange, P.; Bennejean, C.; Renard, P.; Guillaumet, G. Synthesis of 5-substituted-2, 3-dihydro-1, 4-benzoxathiins: biological evaluation as melatonin receptors ligands. J. Enzyme Inhib. Med. Chem. 2003, 18, 187-193.
127. Carocci, A.; Catalano, A.; Lovece, A.; Lentini, G.; Duranti, A.; Lucini, V.; Pannacci, M.; Scaglione, F.; Franchini, C. Design, synthesis, and pharmacological effects of structurally simple ligands for MT1 and MT2 melatonin receptors. Bioorg. Med. Chem. 2010, 18, 6496-6551.
128. Rivara, S.; Lodola, A.; Mor, M.; Bedini, A.; Spadoni, G.; Lucini, V.; Pannacci, M.; Fraschini, F.; Scaglione, F.; Sanchez, R. O.; Gobbi, G.; Tarzia, G. N-(Substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands. J. Med. Chem. 2007, 50, 6618-6626.
129. Li, G.; Zhou, H.; Jiang, Y.; Keim, H.; Topiol, S. W.; Poda, S. B.; Ren, Y.; Chandrasena, G.; Doller, D. Design and synthesis of 4-arylpiperidinyl amide and N-arylpiperdin-3-yl-cyclopropane carbox-amide derivatives as novel melatonin receptor ligands. Bioorg. Med. Chem. Lett. 2011, 21, 1236-1242.
130. Morellato, L.; Lefas-Le Gall, M.; Langlois, M.; Caignard, D.-H.; Renard, P.; Delagrange, P.; Mathe-Allainmat, M. Synthesis of new N-(arylcyclopropyl) acetamides and N-(arylvinyl)acetamides as confor-mationally-restricted ligands for melatonin receptors. Bioorg. Med. Chem. Lett. 2013, 15, 430-434.
131. Davies, D. J.; Garratt, P. J.; Tocher, D. A.; Vonhoff, S.; Davies, J.; Teh, M.-T.; Sugden, D. Mapping the melatonin receptor. 5. Melatonin agonists and antagonists derived from tetrahydrocyclopent-[b]indoles, tetrahydrocarbazoles and hexahydrocyclohept[b]indoles. J. Med. Chem. 1998, 41, 451-467.
132. Spadoni, G.; Balsamini, C.; Diamantini, G.; Di Giacomo, B.; Tarzia, G.; Mor, M.; Plazzi, P. V.; Rivara, S.; Lucini, V.; Nonno, R.; Pannacci, M.; Fraschini, F.; Stankov, B. M. Conformationally restrained melatonin analogs: synthesis, binding affinity for the melatonin receptor, evaluation of the biological activity, and molecular modeling study. J. Med. Chem. 1997, 40, 1990-2002.
133. Jellimann, C.; Mathe-Allainmat, M.; Andrieux, J.; Kloubert, S.; Boutin, J. A.; Nicolas, J. P.; Bennejean, C.; Delagrange, P.; Langlois, M. Synthesis of phenalene and acenaphthene derivatives as new conformationally restricted ligands for melatonin receptors. J. Med. Chem. 2000, 43, 4051-4062.
134. 2-selective melatonin receptor ligands. Bioorg. Med. Chem. 2009, 52, 826-833.
135. Attia, M. I.; Julius, J.; Witt-Enderby, P. A.; Zlotos, D. P. Synthesis and pharmacological evaluation of 13a, 14-dihydro-6H, 13H-pyrazino[1, 2-a;4, 5-a′]diindole analogs as melatonin receptor ligands. Tetrahedron 2007, 63, 754-760.
136. Lucini, V.; Pannacci, M.; Scaglione, F.; Rivara, S.; Mor, M.; Bordi, F.; Plazzi, P. V.; Spadoni, G.; Bedini, A.; Piersanti, G.; Diamantini, G.; Tarzia, G. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity. J. Med. Chem. 2004, 47, 4202-4212.
137. Dubocovich, M. L.; Cardinali, D. P.; Delagrange, P.; Krause, D. N.; Strosberg, A. D.; Sugden, D.; Yocca, F. D. Melatonin Receptors. In The IUPHAR Compendium of Receptor Characterization and Classification, 2nd ed.; Girdlestone, D., Ed.; IUPHAR Media: London, 2000; pp270-277.
138. Lucarini, S.; Bartolucci, S.; Bedini, A.; Gatti, G.; Orlando, P.; Piersanti, G.; Spadoni, G. Synthesis and configuration determination of all enantiopure stereoisomers of the melatonin receptor ligand 4-phenyl-2- propionamidotetralin using an expedient optical resolution of 4-phenyl-2-tetralone. Org. Biomol. Chem. 2012, 10, 305-313.
139. 2 receptor antagonists. Bioorg. Med. Chem. Lett. 2004, 14, 5881-5884.
140. Durieux, S.; Chanu, A.; Bochu, C.; Audinot, V.; Coumailleau, S.; Boutin, J. A.; Delagrange, P.; Caignard, D. H.; Bennejean, C.; Renard, P.; Lesieur, D.; Berthelot, P.; Yous, S. Design and synthesis of 3-phenyltetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. Part II. Bioorg. Med. Chem. 2009, 17, 2963-2974.
141. 2 melatoninergic ligands. Bioorg. Med. Chem. 2008, 16, 8339-8348.
142. Ettaoussi, M.; Sabaouni, A.; Rami, M.; Boutin, J. A.; Delagrange, P.; Renard, P.; Spedding, M.; Caignard, D.-H.; Berthelot, P.; Yous, S. Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I). Eur. J. Med. Chem. 2012, 49, 310-323.
143. 2-selective melatonin receptor ligands. J. Med. Chem. 2006, 49, 7393-7403.
144. Ochoa-Sanchez, R; Comai, S.; Lacoste, B.; Bambico, F. R; Dominguez-Lopez, S.; Spadoni, G; Rvara, S.; Bedini, A; Angeloni, D.; Fraschini, F.; Mor, M.; Tarzia, G; Descarries, L.; Gobbi, G Promotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand. J. Neurosci. 2011, 31, 18452-18439.
145. Hu, Y.; Ho, M. K. C.; Chan, K. H.; New, D. C.; Wong, Y. H. Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT2-selective melatonin ligands. Bioorg. Med. Chem. Lett. 2010, 20, 2582-2585.
146. Hu, Y.; Zhu, J.; Chan, K H; Wong, Y. H. Development of substituted N-[3-(3-methoxyphenyl)propyl] amides as MT2-selective melatonin agonists: improving metabolic stability. Bioorg. Med. Chem. 2013, 21, 547-552.
147. Mesangeau, C.; Fraise, M.; Delagrange, P.; Caignard, D. H.; Boutin, J. A.; Berthelot, P.; Yous, S. Preparation and pharmacological evaluation of a novel series of 2-(phenylthio)benzo[b]thiophenes as selective MT2 receptor ligands. Eur. J. Med. Chem. 2011, 46, 1835-1840.
148. Faust, R; Garratt, P. J.; Jones, R; Yeh, L.-K.; Tsotinis, A.; Panoussopoulou, M.; Calogeropoulou, T.; Teh, M.-T.; Sugden, D. Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6H-isoindolo[2, 1-a]indoles, 5, 6-dihydroindolo[2, 1-a]isoquinolines, and 6, 7-dihydro-5H-benzo[c]-azepino[2, 1-a]indoles. J. Med. Chem. 2000, 43, 1050-1061.
149. Zlotos, D. P.; Attia, M. I.; Julius, J.; Sethi, S.; Witt-Enderby, P. A. 2-[(2, 3-Dihydro-1H-indol-1-yl)methyl] melatonin analogues: a novel class of MT2-selective melatonin receptor antagonists. J. Med. Chem. 2009, 52, 826-833.
150. 2-se-lective melatonin receptor antagonist. Med. Chem. Commun. 2011, 2, 991-994.
151. Descamps-Francois, C.; Yous, S.; Chavatte, P.; Audinot, V.; Bonnaud, A.; Boutin, J. A.; Delagrange, P.; Bennejean, C.; Renard, P.; Lesieur, D. Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands. J. Med. Chem. 2003, 46, 1127-1129.
152. Audinot, V.; Mailliet, F.; Lahaye-Brasseur, C.; Bonnaud, A; Le Gall, A.; Amosse, C.; Dromaint, S.; Rodriguez, M.; Nagel, N; Galizzi, J. P.; Malpaux, B.; Guillaumet, G; Lesieur, D.; Lefoulon, F.; Renard, P.; Delagrange, P.; Boutin, J. A New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 2003, 367, 553-561.
153. Mesangeau, C.; Peres, B.; Descamps-Francois, C.; Chavatte, P.; Audinot, V.; Coumailleau, S.; Boutin, J. A.; Delagrange, P.; Bennejean, C.; Renard, P.; Caignard, D. H; Berthelot, P.; Yous, S. Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT1 melatoninergic ligands. Bioorg. Med. Chem. 2010, 18, 3426-3436.
154. Spadoni, G; Bedini, A; Orlando, P.; Lucarini, S.; Tarzia, G; Mor, M.; Rvara, S.; Lucini, V.; Pannacci, M.; Scaglione, F. Bivalent ligand approach on N-{2-[(3-methoxyphenyl)methylamino]ethyl}-acetamide: synthesis, binding affinity and intrinsic activity forMT1 and MT2 melatonin receptors. Bioorg. Med. Chem. 2011, 19, 4910-4916.
155. Sun, L. Q.; Chen, J.; Bruce, M.; Deskus, J. A; Epperson, J. R; Takaki, K.; Johnson, G; Iben, L.; Mahle, C. D.; Ryan, E.; Xu, C. Synthesis and structure-activity relationship of novel benzoxazole derivatives as melatonin receptor agonists. Bioorg. Med. Chem. Lett. 2004, 14, 3799-3802.
156. Markl, C.; Clafshenkel, W. P.; Attia, M. I.; Sethi, S.; Witt-Enderby, P. A.; Zlotos, D. P. N-Acetyl-5-arylalkoxytryptamine analogs: probing the melatonin receptors for MT1-selectivity. Arch. Pharm. 2011, 334, 666-674.
157. Sabatini, R A.; Guimaraes, P. B.; Fernandes, L.; Reis, F. C.; Bersanetti, P. A.; Mori, M. A.; Navarro, A; Hilzendeger, A. M.; Santos, E. L.; Andrade, M. C.; Chagas, J. R; Pesquero, J. L.; Casarini, D. E.; Bader, M.; Carmona, A. K.; Pesquero, J. B. ACE activity is modulated by kinin B2 receptor. Hypertension 2008, 51, 689-695.
158. Erdos, E. G; Tan, F.; Skidgel, R A. Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function. Hypertension 2010, 55, 214-220.
159. Abadir, P. M.; Periasamy, A; Carey, R M.; Siragy, H. M. Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization. Hypertension 2006, 48, 316-322.
160. Masana, M.; Doolen, S.; Ersahin, C.; Al-Ghoul, W.; Duckles, S.; Dubocovich, M.; Krause, D. MT2 melatonin receptors are present and functional in rat caudal artery. J. Pharmacol. Exp. Ther. 2002, 302, 1295-1302.
161. Yuan, L.; Collins, A. R; Dai, J.; Dubocovich, M. L.; Hill, S. M. MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breastcancer cells. Mol. Cell. Endocrinol. 2002, 192, 147-156.
162. Cillins, A.; Yuan, L.; Kiefer, T. L.; Cheng, Q.; Lai, L.; Hill, S. M. Overexpression of the MT1 melatonin receptor in MCF-7 human breast cancer cells inhibits mammary tumor formation in nude mice. Cancer Lett. 2003, 189, 49-57.
163. Kadekaro, A. L.; Andrade, L. N; Floeter-Winter, L. M.; Rollag, M.; Virador, D.; Vieira, V.; Castrucci, W.; MT-1, A. M. melatonin receptor expression increases the antiproliferative effect of melatonin on S-91 murine melanoma cells. J. Pineal Res. 2004, 36, 204-211.
164. Souza, A V.; Visconti, M. A.; Castrucci, A. M. Melatonin biological activity and binding sites in human melanoma cells. J. Pineal Res. 2003, 34, 242-248.
165. Kobayashi, Y.; Itoh, M. T.; Kondo, H; Okuma, Y.; Sato, S.; Kanishi, Y.; Hamada, N; Kiguchi, K; Ishizuka, B. Melatonin binding sites in estrogen receptor positive cells derived from human endometrial cancer. J. Pineal Res. 2003, 35, 71-74.
166. Jablonska, K; Pula, B.; Zemla, A.; Owczarek, T.; Wojnar, A.; Rys, J.; Ambicka, A.; Podhorska-Okolow, M.; Ugorski, M.; Dziegiel, P. Expression of melatonin receptor MT1 in cells of human invasive ductal breast carcinoma. J. Pineal Res. 2013, 54, 334-345.
167. Oprea-llies, G; Haus, E.; Sackett-Lundeen, L.; Liu, Y.; McLendon, L.; Busch, R; Adams, A.; Cohen, C. Expression of melatonin receptors in triple negative breast cancer (TNBC) in African American and Caucasian women: relation to survival. Breast Cancer Res. Treat. 2013, 137, 677-687.
168. Hill, S.; Cheng, C.; Yuan, L.; Mao, L.; Jockers, R; Dauchy, B.; Blask, D. E. Age-related decline in melatonin and its MT1 receptor are associated with decreased sensitivity to melatonin and enhanced mammary tumor growth. Curr. Aging Sci. 2013, 6, 125-133.
169. Mao, L.; Yuan, L.; Slakey, L. M.; Jones, F. E.; Burrow, M. E.; Hill, S. M. Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. Breast Cancer Res. 2010, 12, R107.
170. Grant, M.; Alturaihi, H; Jaquet, P.; Collier, B.; Kumar, U. Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol. Endocrinol. 2008, 22, 2278-2292.
171. Rozenfeld, R.; Abul-Husn, N. S.; Gomez, I.; Devi, L. A. An emerging role for the delta opioid receptor in the regulation of mu opioid receptor function. TheScientificWorldJournal 2007, 7, 64-73.
172. Walwyn, W.; John, S.; Maga, M.; Evans, C. J.; Hales, T. G. Delta receptors are required for full inhibitory coupling of mu-receptors to voltage-dependent Ca(2+) channels in dorsal root ganglion neurons. Mol. Pharmacol. 2009, 76, 134-143.
173. Snook, L. A.; Milligan, G.; Kieffer, B. L.; Massotte, D. Mu-delta opioid receptor functional interaction: insight using receptor-G protein fusions. J. Pharmacol. Exp. Ther. 2006, 318, 683-690.
174. Evans, R. M.; You, H.; Hameed, S.; Altier, C.; Mezghrani, A.; Bourinet, E.; Zamponi, G. W. Heterodimerization of ORL1 and opioid receptors and its consequences for N-type calcium channel regulation. J. Biol. Chem. 2010, 285, 1032-1040.
175. Kharmate, G.; Rajput, P. S.; Watt, H. L.; Somvanshi, R. K.; Chaudhari, N.; Qiu, X.; Kumar, U. Dissociation of epidermal growth factor receptor and ErbB2 heterodimers in the presence of somatostatin receptor 5 modulate signaling pathways. Endocrinology 2011, 152, 931-945.
176. Imbesi, M.; Uz, T.; Manev, H. Melatonin receptor agonist ramelteon activates the extracellular signal-regulated kinase 1/2 in mouse cerebellar granule cells. Neuroscience 2008, 155, 1160-1164.
177. Savaskan, E.; Olivieri, G.; Meier, F.; Brydon, L.; Jockers, R.; Ravid, R.; Wirz-Justice, A.; Muller-Spahn, F. Increased melatonin 1a receptor immunoreactivity in the hippocampus of Alzheimer's disease patients. J. Pineal Res. 2002, 32, 59-62.
178. Savaskan, E.; Ayoub, M. A.; Ravid, R.; Angeloni, D.; Fraschini, F.; Meier, F.; Eckert, A.; Muller-Spahn, F.; Jockers, R. Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease. J. Pineal Res. 2005, 38, 10-16.
179. Brunner, P.; Sozer-Topcular, N.; Jockers, R.; Ravid, R.; Angeloni, D.; Fraschini, F.; Eckert, A.; Muller-Spahn, F.; Savaskan, E. Pineal and cortical melatonin receptors MT1 and MT2 are decreased in Alzheimer's disease. Eur. J. Histochem. 2006, 50, 311-316.
180. Wu, Y. H.; Ursinus, J.; Zhou, J. N.; Scheer, F. A.; Ai-Min, B.; Jockers, R.; van Heerikhuize, J.; Swaab, D. F. Alterations of melatonin reeptors MT1 and MT2 in the hypothalamic suprachiasmatic nucleus during depression. J. Affective Disord. 2013, 148, 357-367.
181. Adi, N.; Mash, D. C; Ali, Y.; Singer, C.; Shehadeh, L.; Papapetropoulos, S. Melatonin MT1 and MT2 receptor expression in Parkinson's disease. Med. Sci. Monit. 2010, 16, BR61-67.
182. Daulat, A. M.; Maurice, P.; Froment, C.; Guillaume, J. L.; Broussard, C.; Monsarrat, B.; Delagrange, P.; Jockers, R. Purification and identification of G protein-coupled receptor protein complexes under native conditions. Mol. Cell. Proteomics 2007, 6, 835-844.
183. Levoye, A.; Dam, J.; Ayoub, M. A.; Guillaume, J. L.; Couturier, C.; Delagrange, P.; Jockers, R. The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization. EMBO J. 2006, 25, 3012-3023.
184. Weil, Z. M.; Hotchkiss, A. K.; Gatien, M. L.; Pieke-Dahl, S.; Nelson, R. J. Melatonin receptor (MT1) knockout mice display depression-like behaviors and deficits in sensorimotor gating. Brain Res. Bull. 2006, 68, 425-429.
185. Larson, J.; Jessen, R. E.; Zu, T.; Arslan, A. D.; Kurtuncu, M.; Imbesi, M.; Manev, H. Impaired hippocampal long-term potentiation in melatonin MT2 receptor-deficient mice. Neurosci. Lett. 2006, 393, 23-26.
186. Imbesi, M.; Uz, T.; Yildiz, S.; Arslan, A. D.; Manev, H. Drug and regionspecific effects of protracted antidepressant and cocaine treatment on the content of melatonin MT(1) and MT(2) receptor mRNA in the mouse brain. Int. J. Neuroprot. Neuroregener. 2006, 2, 185-189.
187. Boyer, S. B.; Slesinger, P. A. Probing novel GPCR interactions using a combination of FRET and TIRF. Commun. Integr. Biol. 2010, 3, 343-346.
188. Chiueh, C. C.; Andoh, T.; Lai, A. R.; Lai, E.; Krishna, G. Neuroprotective strategies in Parkinson's disease: protection against progressive nigral damage induced by free radicals. Neurotoxic. Res. 2000, 2, 293-310.
189. Lin, C. H.; Huang, J. Y.; Ching, C. H.; Chuang, J. I. Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats. J. Pineal Res. 2008, 44, 205-213.
190. Sharma, R.; McMillan, C. R.; Tenn, C. C.; Niles, L. P. Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease. Brain Res. 2006, 1068, 230-236.
191. Huang, J. Y.; Hong, Y. T.; Chuang, J. I. Fibroblast growth factor 9 prevents MPP+-induced death of dopaminergic neurons and is involved in melatonin neuroprotection in vivo and in vitro. J. Neurochem. 2009, 109, 1400-12.
192. Chuang, J. I.; Chen, T. H. Effect of melatonin on temporal changes of reactive oxygen species and glutathione after MPP(+) treatment in human astrocytoma U373MG cells. J. Pineal Res. 2004, 36, 117-125.
193. Chen, S. T.; Chuang, J. I.; Hong, M. H.; Li, E. I. Melatonin attenuates MPP+-induced neurodegeneration and glutathione impairment in the nigrostriatal dopaminergic pathway. J. Pineal Res. 2002, 32, 262-269.
194. Tonazzini, I.; Trincavelli, M. L.; Storm-Mathisen, J.; Martini, C.; Bergersen, L. H. Co-localization and functional cross-talk between A1 and P2Y1 purine receptors in rat hippocampus. Eur. J. Neurosci. 2007, 26, 890-902.
195. Grymek, K.; Lukasiewicz, S.; Faron-Gorecka, A.; Tworzydlo, M.; Polit, A.; Dziedzicka-Wasylewska, M. Role of silent polymorphisms within the dopamine D1 receptor associated with schizophrenia on D1-D2 receptor hetero-dimerization. Pharmacol. Rep. 2009, 61, 1024-1033.
196. Fiorentini, C.; Busi, C.; Gorruso, E.; Gotti, C.; Spano, P.; Missale, C. Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol. Pharmacol. 2008, 74, 59-69.
197. Murat, B.; Devost, D.; Andres, M.; Mion, J.; Boulay, V.; Corbani, M.; Zingg, H. H.; Guillon, G. V1b and CRHR1 receptor heterodimerization mediates synergistic biological actions of vaso-pressin and CRH. Mol. Endocrinol. 2012, 26, 502-520.
198. Tadavarty, R.; Rajput, P. S.; Wong, J. M.; Kumar, U.; Sastry, B. R. Sleep-deprivation induces changes in GABA(B) and mGlu receptor expression and has consequences for synaptic long-term depression. PLoS One 2012, 6, e24933.
199. Ellis, J.; Pediani, J. D.; Canals, M.; Milasta, S.; Milligan, G. Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J. Biol. Chem. 2006, 281, 38812-38824.
200. Rediger, A.; Piechowski, C. L.; Yi, C. X.; Tarnow, P.; Strotmann, R.; Gruters, A.; Krude, H.; Schoneberg, T.; Tschop, M. H.; Kleinau, G.; Biebermann, H. Mutually opposite signal modulation by hypothalamic heterodimerization of ghrelin and melanocortin-3 receptors. J. Biol. Chem. 2011, 286, 39623-39631.
201. 2 receptor function contribute to type 2 diabetes. Nat. Genet. 2012, 44, 297-301.
202. Ivanova, E. A.; Bechtold, D. A.; Dupre, S. M.; Brennand, J.; Barrett, P.; Luckman, S. M.; Loudon, A. S. I. Altered metabolism in the melatonin-related receptor (GPR50) knockout mouse. Am. J. Physiol.: Endocrinol. Metab. 2008, 94, E176-E182.
203. Bechtold, D. A.; Sidibe, A.; Saer, B. R.; Li, J.; Hand, L. E.; Ivanova, E. A.; Darras, V. M.; Dam, J.; Jockers, R.; Luckman, S. M.; Loudon, A. S. A role for the melatonin-related receptor GPR50 in leptin signaling, adaptive thermogenesis, and torpor. Curr. Biol. 2012, 22, 70-77.